BioMap Collaborated with Sanofi to Co-Develop AI Modules to Advance Drug Discovery for Biotherapeutics Using BioMap’s AI Platform
Shots:
- BioMap will receive a $10M up front and near-term fees & will be eligible to receive ~$1B upon achievement of pre-clinical development, clinical development, regulatory, and commercial milestones
- The collaboration uses BioMap’s custom-built foundational models & world-leading AI expertise and Sanofi’s data, computational innovations in protein engineering, and deep biologics development experience to advanced AI models & protein large language models thus enable biologics design & multiparametric optimization
- BioMap’s AI drug discovery platform integrates foundational large language models & super-scale computing with cutting-edge biotechnology to discover novel targets and design biologics through a deep understanding of proteins
Ref: Globe Newswire | Image: Biomap
Related News:- Sanofi Collaborated with Teva to Co-Develop and Co-Commercialize TEV ‘574 for Inflammatory Bowel Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
